Welcome to our dedicated page for Aspen Aerogels SEC filings (Ticker: ASPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aspen Aerogels, Inc. (NYSE: ASPN) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8‑K, annual reports on Form 10‑K, quarterly reports on Form 10‑Q, and other materials that describe Aspen’s financial condition, risk factors, governance, and key business developments.
For Aspen, which describes itself as a technology leader in sustainability, electrification solutions, and thermal management, Form 10‑K and 10‑Q filings are central sources for understanding segment performance in its Energy Industrial and Thermal Barrier businesses, the role of products such as PyroThin, Cryogel, and Pyrogel, and the company’s exposure to EV and energy infrastructure markets. These reports also reference non‑GAAP measures like Adjusted EBITDA, along with reconciliations to GAAP metrics.
Recent Form 8‑K filings have documented material events such as amendments to Aspen’s Credit, Security and Guaranty Agreement with MidCap Financial, including changes to minimum liquidity covenants, removal of a minimum EBITDA maintenance covenant, and clarifications on mandatory prepayments and acquisition baskets. Other 8‑K filings describe quarterly earnings announcements, financial outlook updates, and executive employment agreements, such as the promotion of an internal successor to Chief Financial Officer and Treasurer.
On Stock Titan, AI‑powered tools can help interpret these filings by summarizing lengthy sections, highlighting covenant changes, and explaining the implications of items like restructuring charges, liquidity thresholds, or executive compensation terms. Users can quickly locate 10‑K and 10‑Q reports for detailed financial data, review Form 4 insider transaction filings when available, and track how Aspen’s disclosures evolve over time in response to conditions in EV and energy infrastructure markets.
This page is a practical starting point for investors, analysts, and researchers who want a structured view of Aspen Aerogels’ regulatory history and the key contractual and governance information disclosed through its SEC filings.
Aspen Aerogels, Inc. disclosed that on December 16, 2025 it and certain subsidiaries entered into Amendment No. 2 to their MidCap Credit, Security and Guaranty Agreement. The amendment raises the minimum liquidity requirement from the greater of $50 million and 85% of the outstanding term loan to the greater of $50 million and 100% of the outstanding term loan, and removes the minimum EBITDA maintenance covenant.
The changes also clarify that mandatory prepayments from asset sale proceeds will reduce scheduled amortization payments in direct order of maturity and reduce the basket for permitted acquisitions under the facility. Aspen Aerogels furnished a press release describing the amendment as an exhibit to this report.
Aspen Aerogels (ASPN) reported an insider transaction by its President and CEO (also a Director). On 11/13/2025, the reporting person sold 56,845 shares of common stock (Transaction Code S) under a pre‑arranged Rule 10b5‑1 trading plan. The plan was adopted on August 11, 2025 to sell a limited number of shares for tax purposes related to a one-time personal real estate transaction.
The sale price reflected a weighted average of $3.23, with trades executed between $3.15 and $3.41. Following the transaction, the reporting person beneficially owns 494,011 equity units, comprising 414,306 shares of common stock and 79,705 restricted stock units. Ownership is reported as Direct (D). The filing includes Exhibit 24.1 (Power of Attorney) and was signed by Attorney‑in‑Fact Glenn Deegan on 11/14/2025.
ASPN filed a Form 144 notice for a proposed sale of 56,845 shares of Common stock through Morgan Stanley Smith Barney LLC, listing an aggregate market value of $194,978.35. The filing lists an approximate sale date of November 13, 2025 on the NYSE.
The shares were acquired on May 28, 2024 via previously exercised stock options from the issuer, with payment made in cash on the same date. Shares outstanding were 82,647,081; this is a baseline figure, not the amount being sold.
Aspen Aerogels (ASPN) filed its Q3 2025 10‑Q, showing a sharp year-over-year contraction. Q3 revenue was $73,017, down from $117,340, with gross profit of $20,799 versus $49,043. The quarter swung to an operating loss of $3,348 and a net loss of $6,334.
For the nine months, revenue was $229,764 versus $329,611 last year, and net loss reached $316,639, primarily due to a $287,567 impairment tied to ceasing construction of the Statesboro, Georgia plant. Total assets fell to $491,395 from $895,144 at year-end, while stockholders’ equity declined to $305,733.
Cash and cash equivalents were $150,722. Debt included a term loan of $99,000 and a revolving balance of $14,252; availability under the revolver was $26.8 million. Two customers represented 72% of year-to-date revenue, and one customer accounted for 69% of accounts receivable. Management states it is in compliance with amended MidCap covenants as of September 30, 2025, but notes no assurance of compliance at the end of Q4 2025.
Aspen Aerogels, Inc. (ASPN) furnished an update on its business by announcing financial results for the third quarter of 2025, for the period ended September 30, 2025. The company attached a detailed press release as Exhibit 99.1.
Information about results is furnished under Item 2.02, while “2025 Financial Outlook” and company background are furnished under Item 7.01. The materials are being furnished, not filed, under the Exchange Act.
Grant Douglas Thoele, CFO & Treasurer of Aspen Aerogels, reported changes in beneficial ownership on 10/01/2025. He was granted 10,273 restricted stock units (RSUs) that convert to one share each upon vesting and now beneficially owns 14,881 shares (comprised of 4,608 currently held shares plus the 10,273 RSUs). He also received 14,563 stock options with a $7.30 exercise price exercisable through 10/01/2035, and 20,547 performance share units (PSUs) that vest after the performance period ending 12/31/2027 and may pay out between 0–200% of target based on Aspen’s total shareholder return versus the Russell 2000. The RSUs and options vest in three equal annual tranches beginning 3/5/2026. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Glenn E. Deegan, Chief Administrative Officer, General Counsel and Corporate Secretary of Aspen Aerogels, Inc. (ASPN), reported equity awards granted on 09/30/2025. The filing shows 11,673 RSUs, 16,416 stock options with a $6.96 exercise price and a 09/30/2035 expiration, and 23,347 performance share units (PSUs). The RSUs and options each vest in three equal annual tranches on 09/30/2026, 09/30/2027 and 09/30/2028. The PSUs vest on 03/05/2028 following a performance period from 01/01/2025 to 12/31/2027, and payout ranges from 0% to 200% of target based on total shareholder return relative to the Russell 2000 components. The reported beneficial ownership counts after the transactions are 11,673 RSUs, 16,416 options, and 23,347 PSUs.
Aspen Aerogels reporting person Grant Thoele filed an initial Form 3 disclosing his beneficial ownership in ASPN. He directly holds 4,608 shares of common stock and holds multiple stock option grants exercisable between 11/02/2031 and 03/05/2035 covering a total of several thousand shares at exercise prices from $7.84 to $52.60. He also holds 12,755 performance share units that vest after a performance period ending 12/31/2027 and pay out based on relative total shareholder return versus the Russell 2000.
Glenn E. Deegan, serving as CAO, General Counsel and Corporate Secretary of Aspen Aerogels, Inc. (ASPN), filed an initial Form 3 dated 09/22/2025 reporting that he does not beneficially own any securities of the issuer. The filing identifies Deegan's address at 30 Forbes Road, Northborough, MA, and was executed on his behalf by Andrew Lauzon, Attorney-in-Fact.
Insider transaction summary for ASPN: Daniel Santhosh, Chief Accounting Officer of Aspen Aerogels, reported the disposition of 1,563 shares of common stock on 09/13/2025 at a price of $6.59 per share. The filing states these shares were withheld by the company to satisfy minimum statutory tax withholding on vesting of restricted stock units (RSUs). After the withholding, Mr. Santhosh beneficially owns a total of 16,316 shares/RSU-equivalents, composed of 3,761 shares of common stock and 12,555 RSUs. The Form 4 was signed by an attorney-in-fact on 09/15/2025.